Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LINC01288 is a long intergenic non-coding RNA transcribed from non-coding regions of the human genome and is more than 200 nucleotides in length. Unlike protein-coding genes, LINC01288 functions as a regulator of gene expression, primarily by interacting with other RNA molecules. In non-small cell lung cancer, LINC01288 is upregulated, facilitating tumor cell viability, migration, growth, and metastatic potential. Mechanistically, LINC01288 binds to and stabilizes IL-6 mRNA, which promotes autocrine induction of IL-6 and subsequent activation of the STAT3 pathway, a driver of tumor progression[4]. This molecular function positions LINC01288 as both a potential prognostic biomarker and a therapeutic target in certain cancers. There is no evidence that LINC01288 codes for a protein or functions as a classical receptor, enzyme, channel, or transporter. Its primary roles described to date are as a post-transcriptional modulator in cancer biology[1][4][5].
Not established. Targeting lncRNAs is an emerging area; current mechanisms would be gene silencing (e.g. RNA interference, antisense oligonucleotides)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1288 (LINC01288).